• 목록
• 답변

ARBORMED, an Innovative New drug Company that recently attracted investment from Ildong Pharmaceutical, said it will accelerate the development of Wilson's disease treatment
and Remicade bio better, a rare disease.

Regarding the research and development of new drug candidates for Wilson's disease, co-CEO Lim Won-bin said, "We will enter the first phase of global clinical trials in 2023
and start developing new drugs with the aim of obtaining approval and release by the U.S. Food and Drug Administration (FDA) in 2026.

Wilson's disease is a disease caused by copper's deposition in the liver, brain, eyes, kidneys, and red blood cells due to the abnormal metabolism of copper in the human body.
Regarding the development of new drug candidates for treatment by Wilson, Avomed plans to enter phase 1 clinical trials in 2023 and then transfer technology to multinational
 pharmaceutical companies after phase 2 clinical trials in 2024.
The company will also proceed with the technology transfer in the second half of next year after pushing for a pharmacokinetics/pharmacology (PK/PD) test to develop Remicade Biobetter,
 treatment for osteoarthritis.
Biobetter is an improved new drug for the original biopharmaceutical.

ARBROMED is in charge of FDA approval, drug price negotiation, and sales and distribution of domestic pharmaceutical and bio companies to enter the U.S. through a local subsidiary in the U.S.
In addition to iCURE's dementia deodorant, United Pharmaceutical's non-small cell lung cancer anticancer drug, and Penmix's treatment for multiple sclerosis are cooperating in the U.S.

Park Kyo-jin, co-CEO of Arbormed, explained, "We plan to prepare global quality and management standards (cGMP) for domestic pharmaceutical bio companies to enter the U.S.
while conducting biological equivalence tests according to U.S. FDA regulations."

ARBORMED's U.S. subsidiary is in charge of FDA approval, drug price negotiation, and sales and distribution of domestic pharmaceutical companies.

ARBORMED completed 6 billion won worth of investment attraction with Ildong Pharmaceutical on the 9th, and formed a joint consultative body to develop and commercialize new drugs,
while also cooperating in business related to entering the U.S. market using ARBORMED Pharmacutics' infrastructure.

Lim Won-bin, co-chairman of ARBORMED, added that he will enter the KOSDAQ market in 2024 after completing Series C by the first half of next year through this investment attraction.